Regeneneron打破了2025年Q4的预期收入,增加了股票,提高了价格目标。 Regeneron beat earnings expectations in Q4 2025, boosting stock and raising price targets.

Regenenron制药公司报告说,2026年1月30日Q4收入丰厚,收入11.44 EPS和38.8亿美元,超过了预期。 Regeneron Pharmaceuticals reported strong Q4 earnings on January 30, 2026, with $11.44 EPS and $3.88 billion in revenue, exceeding expectations. 股票交易额约为775.28美元,市场上限为814.8亿美元,P/E比率为18.65。 The stock, trading around $775.28, has a market cap of $81.48 billion and a P/E ratio of 18.65. JP摩根将其价格目标提高到950美元,以可靠的财务和31.41%的净差值为依据。 JPMorgan raised its price target to $950, citing solid financials and a 31.41% net margin. 机构所有权仍然很高,为83.31%,而勃朗特资本减少了4%的股份。 Institutional ownership remains high at 83.31%, while Bronte Capital reduced its stake by 4%. 优化金融公司获得的新职位,该公司将季度股息增加到每股0.94美元。 Optimize Financial acquired a new position, and the company increased its quarterly dividend to $0.94 per share. 分析师维持“机动购买”评级,目标值788.57美元。 Analysts maintain a "Moderate Buy" rating with a target of $788.57.